TY - JOUR
T1 - Identification and characterization of DM1 patients by a new diagnostic certified assay
T2 - Neuromuscular and cardiac assessments
AU - Valaperta, Rea
AU - Sansone, Valeria
AU - Lombardi, Fortunata
AU - Verdelli, Chiara
AU - Colombo, Alessio
AU - Valisi, Massimiliano
AU - Brigonzi, Elisa
AU - Costa, Elena
AU - Meola, Giovanni
PY - 2013
Y1 - 2013
N2 - The expansion of the specific trinucleotide sequence, [CTG], is the molecular pathological mechanism responsible for the clinical manifestations of DM1. Many studies have described different molecular genetic techniques to detect DM1, but as yet there is no data on the analytical performances of techniques used so far in this disease. We therefore developed and validated a molecular method, "Myotonic Dystrophy SB kit," to better characterize our DM1 population. 113 patients were examined: 20 DM1-positive, 11 DM1/DM2-negative, and13 DM1-negative/DM2-positive, who had a previous molecular diagnosis, while 69 were new cases. This assay correctly identified 113/113 patients, and all were confirmed by different homemade assays. Comparative analysis revealed that the sensitivity and the specificity of the new kit were very high (>99%). Same results were obtained using several extraction procedures and different concentrations of DNA. The distribution of pathologic alleles showed a prevalence of the "classical" form, while of the 96 nonexpanded alleles 19 different allelic types were observed. Cardiac and neuromuscular parameters were used to clinically characterize our patients and support the new genetic analysis. Our findings suggest that this assay appears to be a very robust and reliable molecular test, showing high reproducibility and giving an unambiguous interpretation of results.
AB - The expansion of the specific trinucleotide sequence, [CTG], is the molecular pathological mechanism responsible for the clinical manifestations of DM1. Many studies have described different molecular genetic techniques to detect DM1, but as yet there is no data on the analytical performances of techniques used so far in this disease. We therefore developed and validated a molecular method, "Myotonic Dystrophy SB kit," to better characterize our DM1 population. 113 patients were examined: 20 DM1-positive, 11 DM1/DM2-negative, and13 DM1-negative/DM2-positive, who had a previous molecular diagnosis, while 69 were new cases. This assay correctly identified 113/113 patients, and all were confirmed by different homemade assays. Comparative analysis revealed that the sensitivity and the specificity of the new kit were very high (>99%). Same results were obtained using several extraction procedures and different concentrations of DNA. The distribution of pathologic alleles showed a prevalence of the "classical" form, while of the 96 nonexpanded alleles 19 different allelic types were observed. Cardiac and neuromuscular parameters were used to clinically characterize our patients and support the new genetic analysis. Our findings suggest that this assay appears to be a very robust and reliable molecular test, showing high reproducibility and giving an unambiguous interpretation of results.
UR - http://www.scopus.com/inward/record.url?scp=84878688281&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878688281&partnerID=8YFLogxK
U2 - 10.1155/2013/958510
DO - 10.1155/2013/958510
M3 - Article
C2 - 23762868
AN - SCOPUS:84878688281
VL - 2013
JO - BioMed Research International
JF - BioMed Research International
SN - 2314-6133
M1 - 958510
ER -